MedTrace Logo

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-07-10

No results posted yet for this study

Summary

This study evaluates the use of topical ABI-1968 cream, in the treatment of cervical precancerous lesions in adult women.

Conditions

  • HSIL
  • HSIL of Cervix
  • High-Grade Squamous Intraepithelial Lesions
  • High-grade Cervical Intraepithelial Neoplasia
  • Human Papilloma Virus
  • Cervical Cancer
  • Cervical Intraepithelial Neoplasia
  • Cervical Neoplasm
  • Cervical Dysplasia
  • CIN

Interventions

DRUG

ABI-1968

Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts

Sponsors & Collaborators

  • Antiva Biosciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-10-30
Completion
2018-10-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03239223 on ClinicalTrials.gov